EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors

Filemon S Dela Cruz, Elizabeth Fox, Steven G DuBois iD, Gregory K Friedman iD, James M Croop, AeRang Kim, Daniel A Morgenstern iD, Frank M Balis, Margaret E Macy iD, Joseph G Pressey iD, Tanya Watt, Julie I Krystal iD und 9 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31692 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Filemon S Dela Cruz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Oxford PharmaGenesis Inc., NCI NIH HHS, Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Developing targeted therapies with manageable toxicities remains a high priority for pediatric cancer. We sought to determine the recommended Phase 2 dose (RP2D) and evaluate the antitumor activity of lenvatinib+everolimus in children/young adults with select recurrent/refractory solid tumors.

Methods

Patients 2–21 years old were eligible. Phase 1 used a rolling‐six design. Phase 2 was limited to patients with Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), or high‐grade glioma (HGG), and ≤2 prior VEGF/VEGFR‐targeted therapies. Primary endpoints included the determination of maximum tolerated dose (MTD), RP2D, safety/toxicity (Phase 1), and objective response rate (ORR) per RECIST version 1.1 (RANO for HGG) at Week 16 (Phase 2).

Results

In Phase 1, 23 patients received lenvatinib 11 mg/m 2 (dose level [DL] 1, n = 18) or 8 mg/m 2 (DL −1, n = 5) combined with everolimus 3 mg/m 2 orally once daily. DL1 was declared the MTD/RP2D given dose‐limiting toxicities (proteinuria [ n = 1]; hypertriglyceridemia and hypercholesterolemia [ n = 1]) observed in two of 12 patients treated at DL1. In Phase 2, 41 patients (EWS, n = 10; RMS, n = 20; HGG, n = 11) were treated with the RP2D. Two patients with RMS experienced partial response by Week 16. No other objective responses were observed. Two patients with EWS experienced prolonged disease control (≥23 weeks). No new safety signals were identified. The safety profile was similar to those of treated adults with renal cell carcinoma.

Conclusion

Lenvatinib+everolimus has a manageable safety profile in this pediatric population. Despite unmet efficacy endpoints, the antitumor activity observed in RMS and EWS may warrant further study in select pediatric solid tumors. ClinicalTrials.gov number NCT03245151

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalNeoplasmsDrug Resistance, NeoplasmSarcoma, EwingRhabdomyosarcomaGliomaHumansQuinolinesAdolescentChildFemalePhenylurea CompoundsMaleYoung AdultEverolimusChild, PreschoolFollow-Up StudiesMaximum Tolerated DoseAdultPrognosis

Stichwörter der Autor:innen

Ewing sarcomaeverolimushigh‐grade gliomalenvatinibpediatric solid tumorsrhabdomyosarcoma

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsEverolimus

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pediatrics, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
  • Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pediatric Hematology, Oncology, and Stem Cell Transplant, Riley Hospital for Children, Indianapolis, Indiana, USA.

ORCID-Profile: Steven G DuBois, Gregory K Friedman, Daniel A Morgenstern, Margaret E Macy, Joseph G Pressey, Julie I Krystal, Kieuhoa T Vo, Theodore W Laetsch, Julia L Glade Bender

Förderung

  • Oxford PharmaGenesis Inc.
  • NCI NIH HHS
  • Merck Sharp & Dohme LLC
  • Eisai Inc., Nutley, NJ, USA
  • Merck & Co. Inc., Rahway, NJ, USA

Zitieren

APA

Dela Cruz, F. S., Fox, E., DuBois, S. G., Friedman, G. K., Croop, J. M., Kim, A., Morgenstern, D. A., Balis, F. M., Macy, M. E., Pressey, J. G., Watt, T., Krystal, J. I., Vo, K. T., Mody, R., Laetsch, T. W., Weigel, B. J., O'Hara, K., He, C. S., Aluri, J., …, & Glade Bender, J. L. (2025). A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31692

Vancouver

Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, et al. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31692

BibTeX
@article{DelaCruz2025,
  author = {Dela Cruz, Filemon S and Fox, Elizabeth and DuBois, Steven G and Friedman, Gregory K and Croop, James M and Kim, AeRang and Morgenstern, Daniel A and Balis, Frank M and Macy, Margaret E and Pressey, Joseph G and Watt, Tanya and Krystal, Julie I and Vo, Kieuhoa T and Mody, Rajen and Laetsch, Theodore W and Weigel, Brenda J and O'Hara, Karen and He, Cixin S and Aluri, Jagadeesh and Okpara, Chinyere E and Glade Bender, Julia L},
  title = {A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31692}
}
Kostenlos starten →